Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
Impel NeuroPharma
About
Impel NeuroPharma is a medical device company that develops a novel drug delivery device that uses direct nose-to-brain delivery.
- 51 - 100
Details
- Last Funding Type
- Series D
- Last Funding Money Raised
- $67.50M
- Industries
- Biotechnology,Delivery,Health Care,Medical Device
- Founded date
- Jan 1, 2008
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Impel NeuroPharma is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company’s strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD) system with well-established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 6, 2018 | Series D | $67.50M | 2 |
Norwest Venture Partners
Kohlberg Kravis Roberts
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Norwest Venture Partners
|
Yes | Series D |
|
Kohlberg Kravis Roberts
|
Yes | Series D |
